13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • CP-MGA271-05

    Acronym: 

    CP-MGA271-05

    ACTRN/NCT /ethics: 

    NCT04129320

    Scientific title: 

    A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Summary of trial and patient characteristics

    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Phase II, Phase III Tumour Stream Head and Neck
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2019-10-01
    Molecular Target Anticipated End Date 2025-10-01
    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Phase II, Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Head and Neck
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2019-10-01
    Anticipated End Date 2025-10-01

    Trial Summary

    This is a Phase 2/3, randomized, open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012, with and without chemotherapy, in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The study will be conducted in 2 modules, Module A (Phase 2) and Module B (Phase 3).

    Lay Summary

    A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012, With and Without Chemotherapy, in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Sponsor / Cooperative group

    MacroGenics

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Brian Stein Not Yet Recruiting